Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 in Advanced Solid Tumors
NCT05434234Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- May 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 6
01
Overview
Phase 2, open-label trial of YL201 in solid tumor (advanced stage) (3 arms), sponsored by MediLink Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 36 months and 3 more. Started May 2022; status: recruiting.
02
Drugs
YL201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05434234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434234.